BRVE
Braveheart Bio, Inc. Common Stock
Price Chart
Latest Quote
$29.80
+11.80 (+65.56%)
Current Price
| Previous Close | $18.00 |
| Open | $30.20 |
| Day High | $31.56 |
| Day Low | $29.41 |
| Volume | 3,291,205 |
Stock Information
| Shares Outstanding | 70.65M |
| Total Debt | $667K |
| Cash Equivalents | $80.58M |
| Net Income | $-80.23M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $2.11B |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $978.43M |
| Income | $-80.23M |
| Book/sh | $-2.57 |
| Cash/sh | $1.14 |
Financial Ratios
| Quick Ratio | 8.06 |
| Current Ratio | 8.11 |
| Debt/Eq | 0.93 |
Returns & Margins
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
| P/B | -11.59 |
Analyst Data
| Recommendation | none |
Technical Indicators
| Shares Float | 24.53M |
Performance History
| YTD | +0.00% |
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-08-06 | $29.80 | 3,291,205 |
About Braveheart Bio, Inc. Common Stock
Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM. The company was incorporated in 2024 and is headquartered in San Francisco, California.
đ° Latest News
No news articles available at the moment. Check back later for updates on BRVE.
Period:
Loading...
No financial data available yet. Financial data will be fetched automatically.